Acuta Capital Partners LLC Has $9.49 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Acuta Capital Partners LLC lessened its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 6.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,111,071 shares of the biopharmaceutical company's stock after selling 79,000 shares during the period. Ocular Therapeutix comprises about 9.5% of Acuta Capital Partners LLC's portfolio, making the stock its biggest position. Acuta Capital Partners LLC owned 0.71% of Ocular Therapeutix worth $9,489,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in OCUL. Atlas Capital Advisors Inc. bought a new stake in Ocular Therapeutix in the fourth quarter valued at approximately $43,000. AlphaQuest LLC acquired a new stake in shares of Ocular Therapeutix during the fourth quarter worth $53,000. Tower Research Capital LLC TRC raised its stake in Ocular Therapeutix by 2,045.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock worth $76,000 after buying an additional 8,446 shares during the last quarter. Walleye Capital LLC acquired a new position in Ocular Therapeutix in the fourth quarter valued at $90,000. Finally, XTX Topco Ltd bought a new stake in Ocular Therapeutix during the fourth quarter valued at $99,000. Institutional investors and hedge funds own 59.21% of the company's stock.

Analysts Set New Price Targets

OCUL has been the topic of a number of recent analyst reports. Royal Bank of Canada initiated coverage on Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 price objective on the stock. HC Wainwright reissued a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. JMP Securities set a $19.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Needham & Company LLC reiterated a "buy" rating and set a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. Finally, William Blair started coverage on shares of Ocular Therapeutix in a report on Tuesday, April 8th. They issued an "outperform" rating for the company. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $16.38.

Ocular Therapeutix Stock Up 2.8 %

Shares of NASDAQ OCUL opened at $8.53 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The company has a 50-day moving average price of $7.36 and a 200-day moving average price of $8.44. The stock has a market capitalization of $1.36 billion, a P/E ratio of -6.46 and a beta of 1.49. Ocular Therapeutix, Inc. has a 1 year low of $4.79 and a 1 year high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The company had revenue of $17.08 million for the quarter, compared to analyst estimates of $16.89 million. On average, equities research analysts forecast that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Insider Buying and Selling at Ocular Therapeutix

In related news, insider Pravin Dugel sold 21,475 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $6.87, for a total transaction of $147,533.25. Following the completion of the sale, the insider now directly owns 3,520,318 shares of the company's stock, valued at approximately $24,184,584.66. This trade represents a 0.61 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Donald Notman sold 11,119 shares of the business's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total value of $86,839.39. Following the completion of the transaction, the insider now directly owns 193,444 shares in the company, valued at approximately $1,510,797.64. This represents a 5.44 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 3.50% of the company's stock.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.